The IBTS is to function as a unit to integrate academic resource (infrastructure and expertise) and industrial network to facilitate development of innovative bioinformatics approach to drug discovery, novel biological reagents, unique therapeutic agents, advanced bio-imaging modalities and new biomaterials for diagnosis, prevention and treatment toward Phase-I clinical trials and commercialization.

Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C, He B, Liu B, Shaikh AB, Li F, Wang L, Yang Z, Au DW, Peng S, Zhang Z, Zhang BT, Pan X, Qian A, Shang P, Xiao L, Jiang B, Wong CK, Xu J, Bian Z, Liang Z, Guo DA, Zhu H, Tan W, Lu A (Corresponding author), Zhang G (Corresponding author). Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016 Mar 7;7:10872. doi: 10.1038/ncomms10872 Liang C (Co-first Author), Guo B (Co-first Author), Wu H (Co-first Author), Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DW, Pan X, Zhang BT, Lu C, Zhang H, Yue K, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L (Corresponding Author), Lu A (Corresponding Author), Zhang G (Corresponding Author). Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015 Feb 9. doi: 10.1038/nm.3791. Wang X (Co-first Author), Guo B (Co-first Author), Li Q, Peng J, Yang Z, Wang A, Li D, Hou Z, Lv K, Kan G, Cao H, Wu H, Song J , Pan X, Sun Q, Ling S, Li Y, Zhu M, Zhang P, Peng S, Xie X, Tang T, Hong A, Bian Z, Bai Y, Lu A, Li Y, He F, Zhang G (Corresponding Author), Li Y(Corresponding Author). miR-214 targets ATF4 to inhibit bone formation. Nat Med. 2013 Jan;19(1):93-100. Zhang G (Corresponding Author), Guo B (Co-first Author), Wu H (Co-first Author), Tang T (Co-first Author), Zhang BT (Co-first Author), Zheng L, He Y, Yang Z, Pan X, Chow H, To K, Li Y, Li D,Wang X, Wang Y, Lee K, Hou Z, Dong N, Li G, Leung K, Hung L, He F, Zhang L (Corresponding Author), Qin L (Corresponding Author). A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012 Jan 29;18(2):307-14.